Glaxo Grp England patents expiration
1. Incruse Ellipta patents expiration
INCRUSE ELLIPTA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7498440 | GLAXO GRP ENGLAND | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(1 year, 6 days from now) | |
| US7488827 | GLAXO GRP ENGLAND | Muscarinic acetylcholine receptor antagonists |
Dec, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5873360 | GLAXO GRP ENGLAND | Inhalation device |
Feb, 2016
(8 years ago) | |
| US8309572 | GLAXO GRP ENGLAND | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(1 year, 6 days from now) | |
| US8183257 | GLAXO GRP ENGLAND | Muscarinic acetylcholine receptor antagonists |
Jul, 2025
(1 year, 3 months from now) | |
| US9333310 | GLAXO GRP ENGLAND | Medicament dispenser |
Oct, 2027
(3 years from now) | |
| US8113199 | GLAXO GRP ENGLAND | Counter for use with a medicament dispenser |
Oct, 2027
(3 years from now) | |
| US8161968 | GLAXO GRP ENGLAND | Medicament dispenser |
Feb, 2028
(3 years from now) | |
| US8201556 | GLAXO GRP ENGLAND | Medicament dispenser |
Feb, 2029
(4 years from now) | |
| US8534281 | GLAXO GRP ENGLAND | Manifold for use in medicament dispenser |
Mar, 2030
(5 years from now) | |
| US8746242 | GLAXO GRP ENGLAND | Medicament dispenser |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| M(M-172) | Feb 24, 2019 |
| M(M-245) | Jun 09, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE ingredient
NCE-1 date: 18 December, 2017
Market Authorisation Date: 30 April, 2014
Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.
Dosage: POWDER;INHALATION
More Information on Dosage
INCRUSE ELLIPTA family patents
